Ampio Pharmaceuticals offers $12M in stock to public to fund clinical trial

Tuesday June 18, 2019 0 comments Tags: Englewood, Ampio Pharmaceuticals

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it will offer up to  $12 million  of its common stock in a public offering.Ampio_logoUSE 

Ampio said it has entered into agreements for the purchase of an aggregate 25,320,000 common shares at an offering price of $0.40 per common share for aggregate gross proceeds of $10.1 million before placement agent fees and other offering expenses. 

Ampio said it anticipates an additional 4,680,000 shares of its common stock will be sold at the same price at the close of the offering, expected to close on or about June 19.  

Net proceeds from the offering will be used to cover the full cost of Ampio’s AP-013 clinical trial pursuant to its recently announced Special Protocol Assessment and other general corporate purposes, the company said.

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as exclusive placement agent for the transaction.

A prospectus supplement relating to the offering was filed by the company with the SEC and is available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained from ThinkEquity, 17 State Street, 22nd Floor, New York, NY 10004 (646) 968-9355, Email: [email protected].